Could a gentler drug schedule keep leukemia at bay?
NCT ID NCT07163793
Summary
This study is testing if a shorter, 14-day cycle of the drug venetoclax is easier for patients to tolerate while still keeping their acute myeloid leukemia (AML) in remission. It is for 41 adults with AML who are in remission but cannot receive intensive treatments like stem cell transplants. The main goal is to see if this reduced schedule causes fewer severe side effects, like very low blood counts, compared to the standard longer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zuckerberg Cancer Center
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.